UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )*
Derma Sciences, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $0.01 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
249827205
--------------------------------------------------------------------------------
(CUSIP Number)
Norman H. Pessin
605 Third Avenue-19th Floor
New York, New York 10158
(212) 476-5654
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
February 2,2005
--------------------------------------------------------------------------------
(Date of Event which Requires Filing
of this Statement)
If the filing person has previously filed a statement of Schedule 13G to report
the acquisition which is the subject of the Schedule 13D, and is filing this
schedule because of ss. 240.13d-1(e), ss. 240.13d-1(f) or ss. 240.13d-1(g),
check the following box [ ].
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See ss.240.13d-7(b) for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
(Continued on following page(s))
PAGE 2
CUSIP No. 249827205 Schedule 13D
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SEP IRA F/B/O Norman H. Pessin 092-30-0438
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
PF
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
NUMBER OF SHARES 7 SOLE VOTING POWER 606,000
BENEFICALLY
OWNED BY EACH 8 SHARED VOTING POWER ---------
REPORTING
PERSON WITH 9 SOLE DISPOSITIVE POWER 1,006,000
10 SHARED DISPOSITIVE POWER ---------
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,006,000
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.13%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
PAGE 3
CUSIP No. 249827205 Schedule 13D
Item 1. Security and Issuer
This Schedule 13D relates to the common stock, $.01 par value (the "Common
Stock"), of Derma Sciences, Inc., a Pennsylvania corporation (the "Issuer"),
whose principal executive offices are located at 214 Carnegie Center, Suite 100,
Princeton, New Jersey 08540.
Item 2. Identity and Background
This Schedule 13D is being filed by SEP IRA F/B/O Norman H. Pessin (the
"Reporting Person"). Certain information with respect to the Reporting Person is
set forth below:
Name and Address: SEP IRA F/B/O Norman H. Pessin
605 Third Avenue-19th Floor
New York, New York 10158
Principal Occupation: Retired
Criminal convictions: None
Civil proceedings: None
Citizenship: United States
Item 3. Source and Amount of Funds or Other Consideration
SEP IRA F/B/O Norman H. Pessin purchased 400,000 Units of securities of the
Issuer for $200,000. The Units consist of 1 share of common stock and one
four-year common stock purchase warrant with an exercise price of $1.05 per
share. Previously SEP IRA F/B/O Norman H. Pessin purchased shares of the
issuer's common stock as follows:
Date Number of Shares Price per Share
---- ---------------- ---------------
10/16/03 150,000 $0.967
06/17/04 2,500 $0.70
07/22/04 4,000 $0.70
07/23/04 18,500 $0.70
08/18/04 26,000 $0.50
10/28/04 5,000 $0.65
Item 4. Purposes of the Transactions
The purpose of the acquisitions of securities is investment.
The filer reserved the right to seek changes in the management of the issuer in
the future or in its business. No such plans currently exist.
PAGE 4
CUSIP No. 249827205
Item 5. Interest in Securities of the Issuer
SEP IRA F/B/O Norman H. Pessin owns 606,000 shares of common stock of the
issuer, constituting 6.36% of the outstanding shares thereof. The reporting
person also owns 400,000 common stock purchase warrants to purchase a like
number of shares at an exercise price of $1.05 per share. Therefore the
reporting person has total ownership of 1,006,000 shares, constituting 10.13% of
the class of common stock.
PAGE 5
CUSIP No. 249827205
Item 6. Contracts, Arrangements, Understandings or Relationships with respect to
Securities of the Issuer
None.
Item 7. Material to Be Filed as Exhibits
None.
Signatures
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
SEP IRA F/B/O Norman H. Pessin
By: /s/ Norman H. Pessin
--------------------------
Norman H. Pessin
April 5, 2005